Literature DB >> 10873996

Long term changes in the visual fields of patients with temporal lobe epilepsy using vigabatrin.

P Hardus1, W M Verduin, G Postma, J S Stilma, T T Berendschot, C W van Veelen.   

Abstract

AIM: To study the long term changes in the concentric contraction of the visual field in patients with temporal lobe epilepsy on vigabatrin medication.
METHODS: Repeated Goldmann visual field examinations were compared in 27 patients with drug resistant temporal lobe epilepsy and concentric contraction of the visual field. Two groups were studied: 16 patients who had already stopped vigabatrin medication before surgery and 11 patients who continued vigabatrin medication.
RESULTS: Concentric contraction of the visual field did not change in 16 patients who stopped vigabatrin before the first examination; there was slight but significant progress in visual field loss in 11 patients who continued the use of vigabatrin.
CONCLUSION: Long term follow up of concentric contraction in this selected group of patients indicates that vigabatrin associated visual field loss is not reversible and that progression is possible when vigabatrin is continued.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10873996      PMCID: PMC1723565          DOI: 10.1136/bjo.84.7.788

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN: 0007-1161            Impact factor:   4.638


  13 in total

1.  Severe persistent visual field constriction associated with vigabatrin. Asymptomatic as well as symptomatic defects occur with vigabatrin.

Authors:  R Mackenzie; A Klistorner
Journal:  BMJ       Date:  1998-01-17

2.  Measuring performance in the NHS.

Authors:  M McKee; T Sheldon
Journal:  BMJ       Date:  1998-01-31

3.  Field of dreamers and dreamed-up fields: functional and fake perimetry.

Authors:  J C Thompson; G S Kosmorsky; B D Ellis
Journal:  Ophthalmology       Date:  1996-01       Impact factor: 12.079

4.  Severe persistent visual field constriction associated with vigabatrin. Reaction might be dose dependent.

Authors:  I C Wong; G E Mawer; J W Sander
Journal:  BMJ       Date:  1997-06-07

5.  Severe persistent visual field constriction associated with vigabatrin.

Authors:  T Eke; J F Talbot; M C Lawden
Journal:  BMJ       Date:  1997-01-18

6.  Characteristics of a unique visual field defect attributed to vigabatrin.

Authors:  J M Wild; C Martinez; G Reinshagen; G F Harding
Journal:  Epilepsia       Date:  1999-12       Impact factor: 5.864

7.  Visual field defects associated with vigabatrin therapy.

Authors:  M C Lawden; T Eke; C Degg; G F Harding; J M Wild
Journal:  J Neurol Neurosurg Psychiatry       Date:  1999-12       Impact factor: 10.154

8.  Symptomatic and asymptomatic visual loss in patients taking vigabatrin.

Authors:  H Daneshvar; L Racette; S G Coupland; P J Kertes; A Guberman; D Zackon
Journal:  Ophthalmology       Date:  1999-09       Impact factor: 12.079

9.  Vigabatrin-associated retinal cone system dysfunction: electroretinogram and ophthalmologic findings.

Authors:  G L Krauss; M A Johnson; N R Miller
Journal:  Neurology       Date:  1998-03       Impact factor: 9.910

10.  Automated perimetry and malingerers. Can the Humphrey be outwitted?

Authors:  J F Stewart
Journal:  Ophthalmology       Date:  1995-01       Impact factor: 12.079

View more
  13 in total

1.  Vigabatrin and retinal changes.

Authors:  Hanne Jensen; Ole Sjö; Peter Uldall; Lennart Gram
Journal:  Doc Ophthalmol       Date:  2002-03       Impact factor: 2.379

Review 2.  Vigabatrin.

Authors:  James W Wheless; R Eugene Ramsay; Stephen D Collins
Journal:  Neurotherapeutics       Date:  2007-01       Impact factor: 7.620

3.  Electro-ophthalmological recovery after withdrawal from vigabatrin.

Authors:  Hellen S Graniewski-Wijnands; Kors van der Torren
Journal:  Doc Ophthalmol       Date:  2002-03       Impact factor: 2.379

4.  Visual field and electrophysiological abnormalities due to vigabatrin.

Authors:  Kors van der Torren; Hellen S Graniewski-Wijnands; B C P Polak
Journal:  Doc Ophthalmol       Date:  2002-03       Impact factor: 2.379

5.  New antiepileptic drugs: lacosamide, rufinamide, and vigabatrin.

Authors:  Laura A Strom; Susan Koh; Lauren Frey
Journal:  Curr Treat Options Neurol       Date:  2010-07       Impact factor: 3.598

6.  Objective Derivation of the Morphology and Staging of Visual Field Loss Associated with Long-Term Vigabatrin Therapy.

Authors:  John M Wild; Philip E M Smith; Carlo Knupp
Journal:  CNS Drugs       Date:  2019-08       Impact factor: 5.749

7.  OV329, a novel highly potent γ-aminobutyric acid aminotransferase inactivator, induces pronounced anticonvulsant effects in the pentylenetetrazole seizure threshold test and in amygdala-kindled rats.

Authors:  Malte Feja; Sebastian Meller; Lillian S Deking; Edith Kaczmarek; Matthew J During; Richard B Silverman; Manuela Gernert
Journal:  Epilepsia       Date:  2021-10-07       Impact factor: 5.864

8.  Vigabatrin and visual field defects in pediatric epilepsy patients.

Authors:  Su Jeong You; HyoSook Ahn; Tae-Sung Ko
Journal:  J Korean Med Sci       Date:  2006-08       Impact factor: 2.153

Review 9.  Visual field defects and other ophthalmological disturbances associated with vigabatrin.

Authors:  S J Spence; R Sankar
Journal:  Drug Saf       Date:  2001       Impact factor: 5.228

10.  Treatment of refractory complex partial seizures: role of vigabatrin.

Authors:  Elizabeth J Waterhouse; Kimberly N Mims; Soundarya N Gowda
Journal:  Neuropsychiatr Dis Treat       Date:  2009-10-12       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.